Estrone sulfate (E1S), a prognosis marker for tumor aggressiveness in prostate cancer (PCa)

Journal of Steroid Biochemistry and Molecular Biology

Volumn 109, Issue 1-2, 2008, Pages 158-167

  Giton, Frank ^a   de la Taille, Alexandre ^a   Allory, Yves ^a   Galons, Hervé ^b   Vacherot, Francis ^a   Soyeux, Pascale ^a   Abbou, Claude Clément ^a   Loric, Sylvain ^a   Cussenot, Olivier ^a   Raynaud, Jean Pierre ^c   Fiet, Jean ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c SORBONNE UNIVERSITÉ   (France)

Author keywords

Estrogens; Estrone sulfate; Prostate cancer; Tumor aggressiveness

Indexed keywords

ESTROGEN; ESTRONE SULFATE; PROSTATE SPECIFIC ANTIGEN; ANDROGEN; DRUG DERIVATIVE; ESTRADIOL; ESTRONE; TUMOR MARKER;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE MARKER; ESTROGEN BLOOD LEVEL; GLEASON SCORE; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; BLOOD; BLOOD ANALYSIS; CASE CONTROL STUDY; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; REFERENCE VALUE; STATISTICS;

ADULT; AGED; ANDROGENS; BLOOD CHEMICAL ANALYSIS; CASE-CONTROL STUDIES; ESTRADIOL; ESTRONE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 40849129897     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.10.005     Document Type: Article

References (54)

1. Labrie F., Dupont A., Simard J., Luu-The V., and Belanger A. Intracrinology. The basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol. 24 Suppl. 2 (1993) 94-105
2. Bartsch W., Horst H.-J., Becker H., and Nehse G. Sex hormone binding globulin binding capacity, testosterone, 5alpha-dihydrotestosterone, oestradiol and prolactin in plasma of patients with prostatic carcinoma under various types of hormonal treatment. Acta Endocrinol. 85 3 (1977) 650-664
3. Rannikko S., Kairento A.-L., Karonen A.-L., and Adlercreutz H. Hormonal pattern in prostatic cancer. I. Correlation with local extent of tumour, presence of metastases and grade of differentiation. Acta Endocrinol. 98 4 (1981) 625-633
4. Rannikko S., and Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 4 3 (1983) 223-239
5. Haapiainen R., Rannikko S., Adlercreutz H., and Alfthan O. Correlation of pretreatment plasma levels of estradiol and sex-hormone-binding globulin-binding capacity with clinical stage and survival of patients with prostatic cancer. Prostate 8 2 (1986) 127-137
6. Barrett-Connor E., Garland C., McPhillips J.B., Khaw K.T., and Wingard D.L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer. Cancer Res. 50 1 (1990) 169-173
7. Hsing A.W., and Comstock G.W. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2 1 (1993) 27-32
8. Gann P.H., Hennekens C.H., Ma J., Longcope C., and Stampfer M.J. Prospective study of sex hormone levels and risk of prostate cancer. J. Natl. Cancer. Inst. 88 16 (1996) 1118-1126
9. Nomura A., Heilbrun L.K., Stemmermann G.N., and Judd H.L. Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res. 48 12 (1988) 3515-3517
10. Guess H.A., Friedman G.D., Sadler M.C., Stanczyk F.Z., Vogelman J.H., Imperato-McGinley J., Lobo R.A., and Orentreich N. 5 Alpha-reductase activity and prostate cancer: a case-control study using stored sera. Cancer Epidemiol. Biomarkers Prev. 6 1 (1997) 21-24
11. Vatten L.J., Ursin G., Ross R.K., Stanczyk F.Z., Lobo R.A., Harvei S., and Jellum E. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol. Biomarkers Prev. 6 11 (1997) 967-969
12. Dorgan J.F., Albanes D., Virtamo J., Heinonen O.P., Chandler D.W., Galmarini M., McShane L.M., Barrett M.J., Tangrea J., and Taylor P.R. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol. Biomarkers Prev. 7 12 (1998) 1069-1074
13. Heikkila R., Aho K., Heliovaara M., Hakama M., Marniemi J., Reunanen A., and Knekt P. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 86 2 (1999) 312-315
14. Mohr B.A., Feldman H.A., Kalish L.A., Longcope C., and McKinlay J.B. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 57 5 (2001) 930-935
15. Carter H.B., Pearson J.D., Metter E.J., Chan D.W., Andres R., Fozard J.L., Rosner W., and Walsh P.C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate 27 1 (1995) 25-31
16. Stattin P., Lumme S., Tenkanen L., Alfthan H., Jellum E., Hallmans G., Thoresen S., Hakulinen T., Luostarinen T., Lehtinen M., Dillner J., Stenman U.H., and Hakama M. High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int. J. Cancer 108 3 (2004) 418-424
17. Chen C., Weiss N.S., Stanczyk F.Z., Lewis S.K., DiTommaso D., Etzioni R., Barnett M.J., and Goodman G.E. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the Carotene and Retinol Efficacy Trial. Cancer Epidemiol. Biomarkers Prev. 12 12 (2003) 1410-1416
18. Parsons J.K., Carter H.B., Platz E.A., Wright E.J., Landis P., and Metter E.J. Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. Cancer Epidemiol. Biomarkers Prev. 14 9 (2005) 2257-2260
19. Severi G., Morris H.A., MacInnis R.J., English D.R., Tilley W., Hopper J.L., Boyle P., and Giles G.G. Circulating steroid hormones and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 15 1 (2006) 86-91
20. Ho S.M. Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J. Cell. Biochem. 91 3 (2004) 491-503
21. Leav I., Ho S.M., Ofner P., Merk F.B., Kwan P.W., and Damassa D. Biochemical alterations in sex hormone-induced hyperplasia and dysplasia of the dorsolateral prostates of Noble rats. J. Natl. Cancer Inst. 80 13 (1988) 1045-1053
22. Leav I., Merk F.B., Kwan P.W., and Ho S.M. Androgen-supported estrogen-enhanced epithelial proliferation in the prostates of intact Noble rats. Prostate 15 1 (1989) 23-40
23. Bosland M.C., Ford H., and Horton L. Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol. Carcinogenesis 16 6 (1995) 1311-1317
24. Bosland M.C. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann. NY Acad. Sci. 1089 (2006) 168-176
25. Raghow S., Hooshdaran M.Z., Katiyar S., and Steiner M.S. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res. 62 5 (2002) 1370-1376
26. Cavalieri E.L., Devanesan P., Bosland M.C., Badawi A.F., and Rogan E.G. Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23 2 (2002) 329-333
27. Markushin Y., Gaikwad N., Zhang H., Kapke P., Rogan E.G., Cavalieri E.L., Trock B.J., Pavlovich C., and Jankowiak R. Potential biomarker for early risk assessment of prostate cancer. Prostate 66 14 (2006) 1565-1571
28. Fiet J., Giton F., Ibrahim F., Valleix A., Galons H., and Raynaud J.-P. Development of a highly sensitive and specific new testosterone time-resolved fluoroimmunoassay in human serum. Steroids 69 7 (2004) 461-471
29. Fiet J., Giton F., Boudi A., Boudou P., Soliman H., Villette J.-M., and Galons H. Development of a sensitive and specific new plasma 4-androsten-3,17-dione time-resolved fluroimmunoassay (TR-FIA). Steroids 66 8 (2001) 609-614
30. Fiet J., Morville R., Chemama D., Villette J.-M., Gourmel B., Brerault J.-L., and Dreux C. Plasma androgen and gonadotrophin levels in normal adult men after percutaneous administration of 5α-dihydrotestosterone. Int. J. Androl. 5 (1982) 586-594
31. Tremblay R., and Dube J.Y. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraception. Contraception 10 6 (1974) 599-605
32. Giton F., Fiet J., Guéchot J., Ibrahim F., Bronsard F., Chopin D., and Raynaud J.-P. Serum bioavailable testosterone: assayed or calculated?. Clin. Chem. 52 3 (2006) 474-481
33. Giton F., Valleix A., Boudou P., Villette J.-M., Belanger A., Galons H., and Fiet J. Specific radioimmunoassay of estrone sulfate. Application to measurement in male plasma. J. Steroid Biochem. Mol. Biol. 81 1 (2002) 85-94
34. Labrie F., Bélanger A., Bélanger P., Bérubé R., Martel C., Cusan L., Gomez J., Candas B., Castiel I., Chaussade V., Deloche C., and Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J. Steroid Biochem. Mol. Biol. 99 4-5 (2006) 82-188
35. Nagata C., Takatsuka N., Shimizu H., Hayashi H., Akamatsu T., and Murase K. Effect of soymilk consumption on serum estrogen and androgen concentrations in Japanese men. Cancer Epidemiol. Biomarkers Prev. 10 3 (2001) 179-184
36. Giton F., De la Taille A., Allory Y., Tichet J., Born C., Abbou C.C., and Raynaud J.-P. Plasma E1S and hormone status in prostate adenocarcinoma. Proceedings of the 17th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology. Seefeld, Austria, 31 May-3 June (2006)
37. Vignon F., Terqui M., Westley B., Derocq D., and Rochefort H. Effects of plasma estrogen sulfates in mammary cancer cells. Endocrinology 106 4 (1980) 1079-1086
38. Pasqualini J.R., Gelly C., Nguyen B.L., and Vella C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34 1-6 (1989) 155-163
39. Santner S.J., Levin M.C., and Santen R.J. Estrone sulfate stimulates growth of nitrosomethylurea-induced breast carcinoma in vivo in the rat. Int. J. Cancer 46 1 (1990) 73-78
40. F. Giton, Mémoire pour l'obtention du diplôme de l'Ecole Pratique des Hautes Etudes, Paris, Œstrogènes et Prostate: évaluation de l'Intérêt du sulfate d'œstrone en pathologie prostatique, September 21, 2004.
41. Prost O., Ottignon Y., Rémy-Martin A., Vuitton D., Miguet J.-P., and Adessi G.L. Steroid sulfatase activities in normal and cirrhotic livers and plasma levels of estrone sulfate, estrone and estradiol-17 beta in men. Steroids 43 2 (1984) 189-199
42. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.C., Delalonde L., Talbi M., and Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81 4 (1996) 1460-1464
43. Nakamura Y., Suzuki T., Fukuda T., Ito A., Endo M., Moriya T., Arai Y., and Sasano H. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate 66 9 (2006) 1005-1012
44. Santner S.J., Feil P.D., and Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59 1 (1984) 29-33
45. Risbridger G.P., Bianco J.J., Ellem S.J., and McPherson S.J. Estrogens and prostate cancer. Endocr. Relat. Cancer 10 2 (2003) 187-191
46. Purohit A., Duncan L.J., Wang D.Y., Coldham N.G., Ghilchik M.W., and Reed M.J. Paracrine control of estrogen production in breast cancer. Endocr. Relat. Cancer 4 (1997) 323-330
47. Purohit A., Newman S.P., and Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res. 4 2 (2002) 65-69
48. Purohit A., Chapman O., Duncan L., and Reed M.J. Modulation of estrone sulphatase activity in breast cell lines by growth factors. J. Steroid Biochem. Mol. Biol. 41 3-8 (1992) 563-566
49. Reed M.J., Purohit A., Woo L.W., Newman S.P., and Potter B.V. Steroid sulfatase: molecular biology, regulation and inhibition. Endocr. Rev. 26 2 (2005) 171-202
50. Pasqualini J.R., Chetrite G., Nguyen B.L., Maloche C., Delalonde L., Talbi M., Feinstein M.C., Blacker C., Botella J., and Paris J. Estrone sulfate-sulfatase and 17 beta-hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone-dependence to hormone-independence. J. Steroid Biochem. Mol. Biol. 53 1-6 (1995) 407-412
51. Soronen P., Laiti M., Törn S., Härkönen P., Patrikainen L., Li Y., Pulkka A., Kurkela R., Herrala A., Kaija H., Isomaa V., and Vihko P. Sex steroid hormone metabolism and prostate cancer. J. Steroid Biochem. Mol. Biol. 92 4 (2004) 281-286
52. Vihko P., Herrala A., Härkönen P., Isomaa V., Kaija H., Kurkela R., Li Y., Patrikainen L., Pulkka A., Soronen P., and Törn S. Enzymes as modulators in malignant transformation. J. Steroid Biochem. Mol. Biol. 93 2-5 (2005) 277-283
53. Vihko P., Herrala A., Härkönen P., Isomaa V., Kaija H., Kurkela R., and Pulkka A. Control of cell proliferation by steroids: the role of 17HSDs. Mol. Cell Endocrinol. 248 1-2 (2006) 141-148
54. Pasqualini J.R., and Chétrite G. Activity, regulation and expression of sulfatase, sulfotransferase, and 17β-hydroxysteroid dehydrogenase in breast cancer. In: Pasqualini R., and Katzenellenbogen B.S. (Eds). Hormone-dependent Cancer (1996), Marcel Dekker, Inc., New York/Basel/Hong Kong 25-80